HK1068266A1 - Use of nk-1 receptor antagonists for the treatmentof brain, spinal or nerve injury - Google Patents

Use of nk-1 receptor antagonists for the treatmentof brain, spinal or nerve injury

Info

Publication number
HK1068266A1
HK1068266A1 HK05100430A HK05100430A HK1068266A1 HK 1068266 A1 HK1068266 A1 HK 1068266A1 HK 05100430 A HK05100430 A HK 05100430A HK 05100430 A HK05100430 A HK 05100430A HK 1068266 A1 HK1068266 A1 HK 1068266A1
Authority
HK
Hong Kong
Prior art keywords
treatmentof
spinal
brain
receptor antagonists
nerve injury
Prior art date
Application number
HK05100430A
Other languages
English (en)
Inventor
Torsten Hoffmann
Ala John Nimmo
Andrew Sleight
Pierre Vankan
Robert Vink
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1068266A1 publication Critical patent/HK1068266A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
HK05100430A 2001-07-10 2005-01-17 Use of nk-1 receptor antagonists for the treatmentof brain, spinal or nerve injury HK1068266A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01116812 2001-07-10
PCT/EP2002/007323 WO2003006016A2 (en) 2001-07-10 2002-07-03 Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury

Publications (1)

Publication Number Publication Date
HK1068266A1 true HK1068266A1 (en) 2005-04-29

Family

ID=8178001

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05100430A HK1068266A1 (en) 2001-07-10 2005-01-17 Use of nk-1 receptor antagonists for the treatmentof brain, spinal or nerve injury

Country Status (24)

Country Link
US (3) US20030083345A1 (xx)
EP (2) EP1406618A2 (xx)
JP (1) JP2004536119A (xx)
KR (1) KR100589106B1 (xx)
CN (1) CN100346789C (xx)
AR (1) AR037008A1 (xx)
AU (1) AU2002328837B2 (xx)
BR (1) BR0210893A (xx)
CA (1) CA2451566C (xx)
GT (1) GT200200143A (xx)
HK (1) HK1068266A1 (xx)
HR (1) HRP20031071A2 (xx)
HU (1) HUP0401210A3 (xx)
IL (1) IL159350A0 (xx)
MX (1) MXPA04000278A (xx)
NO (1) NO332847B1 (xx)
NZ (1) NZ530107A (xx)
PA (1) PA8549901A1 (xx)
PE (1) PE20030238A1 (xx)
PL (1) PL211246B1 (xx)
RU (1) RU2304435C2 (xx)
UY (1) UY27374A1 (xx)
WO (1) WO2003006016A2 (xx)
ZA (1) ZA200400138B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ303639B6 (cs) * 2000-07-14 2013-01-23 F. Hoffmann-La Roche Ag N-Oxid derivátu 4-fenylpyridinu, zpusob jeho prípravy a lécivo s jeho obsahem
CA2530886C (en) * 2003-07-03 2013-05-28 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
CA2572645C (en) 2004-07-06 2011-01-18 F. Hoffmann-La Roche Ag Process for preparing carboxamide derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
MX2007010034A (es) * 2005-02-22 2007-10-04 Hoffmann La Roche Antagonista de nk1.
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
ES2320590T3 (es) * 2005-03-23 2009-05-25 F. Hoffmann-La Roche Ag Metabolitos para antagonistas nk-1 para emesis.
SI1945632T1 (sl) 2005-11-08 2014-03-31 Vertex Pharmaceuticals Incorporated Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
DE102007018151A1 (de) * 2007-04-16 2008-10-23 Günenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
JP5497633B2 (ja) 2007-05-09 2014-05-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒのモジュレーター
AU2008278273A1 (en) * 2007-07-19 2009-01-22 Adelaide Research & Innovation Pty Ltd Method for reducing intracranial pressure
WO2009076142A2 (en) 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
WO2009073757A1 (en) 2007-12-07 2009-06-11 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
CA3039943C (en) 2008-02-28 2021-07-13 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
CA2795804C (en) 2010-04-07 2021-10-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
EP3016658A4 (en) * 2013-07-02 2017-03-15 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-iv
RU2016103099A (ru) * 2013-07-02 2017-08-07 Юстрэлиз Фармасьютикалз Лимитед (Трейдинг Эз Пресшура Нейро) Способ предотвращения и/или лечения хронической травматической энцефалопатии - i
EP3016657B1 (en) * 2013-07-02 2019-06-26 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-ii
EP3067349B1 (en) 2013-11-08 2018-02-28 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
CA2930199C (en) 2013-11-12 2022-10-25 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
PT3221692T (pt) 2014-11-18 2021-09-10 Vertex Pharma Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
JP7400180B2 (ja) * 2018-02-02 2023-12-19 ユーストラリス ファーマシューティカルズ リミテッド （トレーディング アズ プレススラ ニューロ） 非経口製剤及びその使用
KR101970099B1 (ko) * 2018-02-07 2019-04-17 한국과학기술연구원 척수 손상의 예방 및 치료용 조성물
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
EP4017589A4 (en) * 2019-08-23 2023-09-20 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) THERAPEUTIC PROCEDURES AND THEIR APPLICATIONS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd History of piperidine, their preparation and the pharmaceutical preparations containing them
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
US5607947A (en) * 1995-02-21 1997-03-04 Eli Lilly And Company Pyrrolidinyl tachykinin receptor antagonists
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
TW382017B (en) * 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
US6214846B1 (en) * 1997-06-27 2001-04-10 Merck Sharp & Dohme Limited Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
ATE277905T1 (de) * 1999-02-24 2004-10-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
AU772446B2 (en) * 1999-02-24 2004-04-29 F. Hoffmann-La Roche Ag 3-phenylpyridine derivatives and their use as NK-1 receptor antagonists
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
ES2208205T3 (es) * 1999-11-29 2004-06-16 F. Hoffmann-La Roche Ag 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida.
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment

Also Published As

Publication number Publication date
UY27374A1 (es) 2003-03-31
BR0210893A (pt) 2004-06-22
WO2003006016A3 (en) 2003-07-31
CN1523988A (zh) 2004-08-25
US20060247240A1 (en) 2006-11-02
MXPA04000278A (es) 2004-05-04
PL211246B1 (pl) 2012-04-30
ZA200400138B (en) 2005-06-29
CN100346789C (zh) 2007-11-07
WO2003006016A2 (en) 2003-01-23
AR037008A1 (es) 2004-10-20
JP2004536119A (ja) 2004-12-02
NO20040057L (no) 2004-01-07
US20030083345A1 (en) 2003-05-01
NZ530107A (en) 2006-01-27
AU2002328837B2 (en) 2005-05-05
US20110053954A1 (en) 2011-03-03
CA2451566A1 (en) 2003-01-23
HRP20031071A2 (en) 2004-06-30
PE20030238A1 (es) 2003-03-19
GT200200143A (es) 2002-11-11
EP1406618A2 (en) 2004-04-14
KR20040029362A (ko) 2004-04-06
RU2304435C2 (ru) 2007-08-20
HUP0401210A2 (hu) 2004-10-28
CA2451566C (en) 2013-09-10
PA8549901A1 (es) 2003-01-24
KR100589106B1 (ko) 2006-06-14
HUP0401210A3 (en) 2011-07-28
EP1621195A2 (en) 2006-02-01
NO332847B1 (no) 2013-01-21
RU2004102397A (ru) 2005-04-20
IL159350A0 (en) 2004-06-01
EP1621195A3 (en) 2010-01-06
PL369535A1 (en) 2005-05-02

Similar Documents

Publication Publication Date Title
HK1068266A1 (en) Use of nk-1 receptor antagonists for the treatmentof brain, spinal or nerve injury
HK1054872A1 (en) Brain, spinal and nerve injury treatment
HK1066534A1 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
PL363907A1 (en) Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
PL373626A1 (en) Treatment for central nervous system disorders
EP1420854A4 (en) TREATMENT OF NEUROPSYCHIATRIC DISORDERS BY NERVE STIMULATION NEAR THE DIAPHRAGM
HK1152243A1 (en) Vegf for use in the treatment of central nervous system disorders vegf
EP1705988A4 (en) IMMUNOMODULATING COMPOUNDS FOR THE TREATMENT OF THE CENTRAL NERVOUS SYSTEM
GB0428462D0 (en) Spinal cord stimulation as treatment for functional bowel disorders
EP1399160A4 (en) NR2B RECEPTOR ANTAGONISTS FOR TREATING OR PREVENTING MIGRAINE
MXPA03009644A (es) Grupos azabiciclicos sustituidos para el tratamiento de enfermedades.
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
ZA200402514B (en) 4[Piperidin-4-yliden-(3-carbamoylphenyl)methyl]benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders.
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
IL162475A0 (en) Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
ZA200509169B (en) Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
IL162053A0 (en) Method for the treatment of bone disorders
WO2004048318A8 (en) Improved process for the preparation of 1,3-substituted indenes
HK1040933A1 (zh) N-取代的氮雜二環烷衍生物在治療中樞神經系統疾病中的應用
AU2003245995A8 (en) Use of gaba-c receptor antagonists for the treatment of myopia
TW390191U (en) Examining device for nerves of the spinal cord
PL374077A1 (en) Use of 5-ht2 receptor antagonists for the treatment of sleep disorders

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110703